Dyne Therapeutics (DYN) Current Assets (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Current Assets of $937.9 million for Q2 2026, up 34.38% year-over-year from $697.9 million in Q2 2025, and down 8.14% quarter-over-quarter from $1.0 billion in Q1 2026.
Dyne Therapeutics (DYN) Current Assets (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Current Assets for 8 consecutive years, with $937.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets rose 34.38% year-over-year to $937.9 million; the TTM figure through Jun 2026 stood at $937.9 million (up 34.38% YoY), while the FY2025 annual figure was $1.1 billion, up 70.88% from the prior year.
- Current Assets eased to $937.9 million in Q2 2026 per DYN's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Current Assets topped out at $1.1 billion in Q4 2025 and bottomed at $129.4 million in Q4 2023.
- Historically, Current Assets has averaged $549.0 million across 5 years, with a median of $573.7 million in 2024.
- Annual changes were most pronounced in 2023 — Current Assets sank 51.29% — and 2024, when it jumped 409.59%.
- Dyne Therapeutics' Current Assets stood at $265.6 million in 2022, then tumbled by 51.29% to $129.4 million in 2023, then surged by 409.59% to $659.3 million in 2024, then soared by 70.88% to $1.1 billion in 2025, then retreated by 16.75% to $937.9 million in 2026.
- Business Quant data shows DYN's Current Assets at $937.9 million in Q2 2026, $1.0 billion in Q1 2026, and $1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 937.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 937.89 Mn |
| Mar 31, 2026 | 1.02 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 806.26 Mn |
| Jun 30, 2025 | 697.95 Mn |
| Mar 31, 2025 | 689.50 Mn |
| Dec 31, 2024 | 659.28 Mn |
| Sep 30, 2024 | 736.39 Mn |
| Jun 30, 2024 | 792.32 Mn |
| Mar 31, 2024 | 488.14 Mn |
| Dec 31, 2023 | 129.38 Mn |
| Sep 30, 2023 | 168.22 Mn |
| Jun 30, 2023 | 213.17 Mn |
| Mar 31, 2023 | 249.21 Mn |
| Dec 31, 2022 | 265.59 Mn |
| Sep 30, 2022 | 258.23 Mn |
| Jun 30, 2022 | 297.93 Mn |
| Mar 31, 2022 | 344.45 Mn |
| Dec 31, 2021 | 382.39 Mn |
| Sep 30, 2021 | 424.66 Mn |